Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CNMD Stock Forecast 2025-2026
$58.62
Current Price
$1.81B
Market Cap
Buy 2
Hold 5
Sell 0
Wall St Analyst Ratings
Distance to CNMD Price Targets
+36.5%
To High Target of $80.00
-1.1%
To Median Target of $58.00
-6.2%
To Low Target of $55.00
CNMD Price Momentum
+2.7%
1 Week Change
+22.0%
1 Month Change
-22.4%
1 Year Change
-14.3%
Year-to-Date Change
-25.4%
From 52W High of $78.58
+27.4%
From 52W Low of $46.00
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching CONMED (CNMD) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on CNMD and similar high-potential opportunities.
Latest CNMD Stock Price Targets & Analyst Predictions
Based on our analysis of 10 Wall Street analysts, CNMD has a neutral consensus with a median price target of $58.00 (ranging from $55.00 to $80.00). The overall analyst rating is Buy (6.6/10). Currently trading at $58.62, the median forecast implies a -1.1% downside. This outlook is supported by 2 Buy, 5 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Matt O'Brien at Piper Sandler, projecting a 36.5% upside. Conversely, the most conservative target is provided by Rick Wise at Stifel, suggesting a 6.2% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CNMD Analyst Ratings
2
Buy
5
Hold
0
Sell
CNMD Price Target Range
Low
$55.00
Average
$58.00
High
$80.00
Current: $58.62
Latest CNMD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CNMD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 1, 2025 | Wells Fargo | Vik Chopra | Equal-Weight | Maintains | $57.00 |
| May 1, 2025 | JP Morgan | Robbie Marcus | Neutral | Maintains | $58.00 |
| May 1, 2025 | Needham | Mike Matson | Buy | Maintains | $61.00 |
| Apr 28, 2025 | Stifel | Rick Wise | Hold | Downgrade | $55.00 |
| Feb 6, 2025 | JP Morgan | Robbie Marcus | Neutral | Downgrade | $70.00 |
| Feb 6, 2025 | Wells Fargo | Vik Chopra | Equal-Weight | Maintains | $70.00 |
| Feb 6, 2025 | Needham | Mike Matson | Buy | Maintains | $91.00 |
| Feb 6, 2025 | Stifel | Rick Wise | Buy | Maintains | $75.00 |
| Oct 31, 2024 | Needham | Mike Matson | Buy | Reiterates | $97.00 |
| Oct 4, 2024 | Needham | Mike Matson | Buy | Reiterates | $97.00 |
| Aug 1, 2024 | Piper Sandler | Matt O'Brien | Overweight | Maintains | $80.00 |
| Aug 1, 2024 | Stifel | Rick Wise | Buy | Maintains | $76.00 |
| Aug 1, 2024 | Wells Fargo | Vik Chopra | Equal-Weight | Maintains | $71.00 |
| Aug 1, 2024 | Needham | Mike Matson | Buy | Maintains | $97.00 |
| Jul 25, 2024 | Needham | Mike Matson | Buy | Maintains | $106.00 |
| May 6, 2024 | Needham | Mike Matson | Buy | Reiterates | $107.00 |
| Apr 25, 2024 | Needham | Mike Matson | Buy | Maintains | $107.00 |
| Apr 25, 2024 | Piper Sandler | Matt O'Brien | Overweight | Maintains | $95.00 |
| Apr 25, 2024 | JP Morgan | Robbie Marcus | Overweight | Maintains | $75.00 |
| Apr 25, 2024 | Wells Fargo | Vik Chopra | Equal-Weight | Maintains | $77.00 |
Conmed Corporation (CNMD) Competitors
The following stocks are similar to CONMED based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Conmed Corporation (CNMD) Financial Data
Conmed Corporation has a market capitalization of $1.81B with a P/E ratio of 15.4x. The company generates $1.32B in trailing twelve-month revenue with a 9.0% profit margin.
Revenue growth is +2.9% quarter-over-quarter, while maintaining an operating margin of +7.3% and return on equity of +13.0%.
Valuation Metrics
Market Cap
$1.81B
Enterprise Value
$2.71B
P/E Ratio
15.4x
PEG Ratio
12.1x
Price/Sales
1.4x
Growth & Margins
Revenue Growth (YoY)
+2.9%
Gross Margin
+55.3%
Operating Margin
+7.3%
Net Margin
+9.0%
EPS Growth
-69.4%
Financial Health
Cash/Price Ratio
+2.0%
Current Ratio
2.3x
Debt/Equity
91.3x
ROE
+13.0%
ROA
+4.1%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Conmed Corporation (CNMD) Business Model
About Conmed Corporation
What They Do
Develops and supplies surgical devices and equipment.
Business Model
Conmed Corporation generates revenue by providing innovative surgical solutions and advanced surgical tools to healthcare facilities such as hospitals and surgical centers. The company's diverse product portfolio, which includes energy systems and minimally invasive instrumentation, allows it to cater to various medical specialties and improve surgical outcomes.
Additional Information
Headquartered in Utica, New York, Conmed focuses on research and development, as well as strategic acquisitions and partnerships, to enhance its market position and adapt to the evolving demands of the healthcare industry.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
3,900
CEO
Mr. Patrick J. Beyer
Country
United States
IPO Year
1990
Website
www.conmed.comConmed Corporation (CNMD) Latest News & Analysis
Latest News
Quick Summary
Zacks Style Scores can assist investors in selecting strong, market-beating stocks for their portfolios.
Why It Matters
Zacks Style Scores can guide stock selection, potentially leading to better returns, influencing investment strategies and portfolio performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
CONMED Corporation (NYSE:CNMD) will hold its Q1 2025 Earnings Conference Call on April 30, 2025, at 4:30 PM ET, featuring CEO Pat Beyer and CFO Todd Garner.
Why It Matters
CONMED's Q1 earnings call provides insights into financial performance, growth strategies, and market positioning, which can impact stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
CONMED Corporation (NYSE: CNMD) reported Q1 2025 sales of $321.3 million, a 2.9% increase YoY. Domestic revenue rose 4.2%. Diluted EPS was $0.19.
Why It Matters
CONMED Corporation's steady revenue growth and positive earnings per share indicate financial health, potentially boosting investor confidence and impacting stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Conmed (CNMD) reported Q3 earnings of $0.95 per share, surpassing the Zacks estimate of $0.81 and up from $0.79 per share year-over-year.
Why It Matters
Conmed's earnings beat estimates and show year-over-year growth, indicating strong financial performance and potentially boosting investor confidence and stock value.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Conmed (CNMD) reported its quarterly earnings for March 2025, indicating a need for analysis of key metrics against Wall Street estimates and previous year's performance.
Why It Matters
Comparing Conmed's quarterly performance against Wall Street estimates and previous year metrics can indicate growth trends and market expectations, influencing stock valuation and investor sentiment.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
CNMD reports strong first-quarter results, with sales growth in both segments.
Why It Matters
Strong first-quarter results and improved sales indicate CNMD's growth potential, likely boosting investor confidence and positively impacting stock performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About CNMD Stock
What is Conmed Corporation's (CNMD) stock forecast for 2025?
Based on our analysis of 10 Wall Street analysts, Conmed Corporation (CNMD) has a median price target of $58.00. The highest price target is $80.00 and the lowest is $55.00.
Is CNMD stock a good investment in 2025?
According to current analyst ratings, CNMD has 2 Buy ratings, 5 Hold ratings, and 0 Sell ratings. The stock is currently trading at $58.62. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CNMD stock?
Wall Street analysts predict CNMD stock could reach $58.00 in the next 12 months. This represents a -1.1% decrease from the current price of $58.62. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Conmed Corporation's business model?
Conmed Corporation generates revenue by providing innovative surgical solutions and advanced surgical tools to healthcare facilities such as hospitals and surgical centers. The company's diverse product portfolio, which includes energy systems and minimally invasive instrumentation, allows it to cater to various medical specialties and improve surgical outcomes.
What is the highest forecasted price for CNMD Conmed Corporation?
The highest price target for CNMD is $80.00 from Matt O'Brien at Piper Sandler, which represents a 36.5% increase from the current price of $58.62.
What is the lowest forecasted price for CNMD Conmed Corporation?
The lowest price target for CNMD is $55.00 from Rick Wise at Stifel, which represents a -6.2% decrease from the current price of $58.62.
What is the overall CNMD consensus from analysts for Conmed Corporation?
The overall analyst consensus for CNMD is neutral. Out of 10 Wall Street analysts, 2 rate it as Buy, 5 as Hold, and 0 as Sell, with a median price target of $58.00.
How accurate are CNMD stock price projections?
Stock price projections, including those for Conmed Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 15, 2025 9:43 PM UTC